microRNA-140: A miRNA with diverse roles in human diseases - 03/03/21
pages | 12 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | This miRNA has been shown to be down-regulated in a diversity of cancers. |
• | miR-140 has a lot of immune-related targets. |
• | A number of miR-140 targets regulate cell proliferation, cell cycle transition and apoptosis. |
• | This miRNA is sponged by a number of lncRNAs and circRNAs. |
• | miR-140 has essential roles in the determination of sensitivity of neoplastic cells to chemotherapeutic agents. |
Abstract |
MicroRNA-140 (miR-140) has been shown to be associated with the pathogenesis of a wide range of pathologies including osteoarthritis, osteoporosis, renal fibrosis, ischemic conditions, and most importantly neoplasia. This miRNA has been shown to be down-regulated in a diversity of cancers namely breast cancer, gastrointestinal cancers, lung cancer, and prostate cancer. miR-140 has a lot of immune-related targets. Moreover, several miR-140 targets regulate cell proliferation, cell cycle transition, and apoptosis. This miRNA has been shown to be sponged by a number of lncRNAs and circ-RNAs. miR-140 has essential roles in the determination of the sensitivity of neoplastic cells to chemotherapeutic agents such as temozolomide, doxorubicin, and cisplatin. Besides, expression quantities of miR-140 in cancer tissues can be used for the prediction of clinical outcomes of patients with neoplasia. In the present paper, we describe the impact of miR-140 in neoplastic and non-neoplastic disorders.
Le texte complet de cet article est disponible en PDF.Keywords : miR-140, Carcinogenesis, Osteoarthritis, Atherosclerosis, Ischemia, Diabetes
Plan
Vol 135
Article 111256- mars 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?